Annelieke Peters (PhD ERT) is a passionate expert in drug development with a focus on toxicology. Her 20 years of experience spans several positions at Biotech and large pharma, working with gene therapy products, as well as large and small molecules.
In her career, she transitioned numerous drugs from preclinical to phase 1 (and beyond), and participated in scientific advice meetings with the FDA, EMA and local authorities. Annelieke has experience with all phases of drug discovery and development, including designing and executing nonclinical drug development programs, Environmental Risk Assessment reports (ERA’s) and she has submitted multiple Marketing Applications (MAA/NDA) and Paediatric Investigation Plans (PIPs).
Pediatric drug development (juvenile animal studies, PDCO interactions) has been a key focus area for Annelieke. She has helped to bring several drugs for children to the market.